CFTR antibody | knockout validation | Abcam ab2784
DOI
//dx.doi.org/10.13070/ko.en.7.2175
Date
2017-03-16

This is a knockout-validated antibody summary, based on the publication "A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

CFTR antibody | knockout validation | Abcam ab2784 figure 1
Figure 1. Representative immunoblots of the indicated proteins in the control CftrF508del/− treatment group. From [1]
Antibody information

Mouse monoclonal IgM

Company: Abcam

Antibody: CFTR

Catalog number: ab2784

Summary: Mouse monoclonal IgM against a synthetic peptide corresponding to human CFTR aa 103-117 (first extracellular loop). Reacts with human, mouse, rat, chicken, guinea pig, and pig. Predicted to work with sheep, rabbit, horse, cow, dog, chimpanzee, Rhesus monkey, gorilla.

Suitable for western blot, immunoprecipitation, immunocytochemistry/immunofluorescence, immunohistochemistry (paraffin), inhibition assay, and flow cytometry.

CFTR antibody | knockout validation | Abcam ab2784 figure 2
Figure 2. Representative immunoblots of the indicated proteins in the Cftr−/− mouse treatment group. From [1].
Validation Method

Western blot

Sample

Control (CftrF508del/−) and Cftr−/− mouse.

Primary incubation

1:1,000 dilution.

Clone note

The same clone (CF3) is sold as Novus Biologicals NB300-511; Abcam ab2784; Invitrogen MA1-935.

References
  1. Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ. 2016;23:1380-93 pubmed publisher